U.S. Markets closed

Lipocine Inc. (LPCN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.2000-0.0600 (-4.76%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2600
Open1.2500
Bid1.1900 x 1100
Ask1.2100 x 2200
Day's Range1.1500 - 1.2500
52 Week Range0.3010 - 2.9600
Volume1,036,817
Avg. Volume3,672,995
Market Cap78.822M
Beta (5Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-0.5050
Earnings DateNov 10, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America
    PR Newswire

    Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present results from studies suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men as well as the safety and efficacy of TLANDO™, an oral testosterone replacement therapy without a dose titration requirement, at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America ("SMSNA"). Lipocine will outline the possible mechanisms and clinical evidence that suggests men with low testosterone have poor COVID-19 outcomes, and the rationale of using an oral testosterone therapy for men with COVID-19. Results from the previously completed dose validation ("DV") study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting. The presentations will take place virtually on November 9, 2020 from 7:00 p.m. – 9:00 p.m. EST during Session 2 (Androgens and Ejaculation/Orgasm Disorders).

  • Lipocine to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
    PR Newswire

    Lipocine to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, will provide an update on LPCN 1144, an oral product of bioidentical testosterone being evaluated for the treatment of non-cirrhotic, NASH at the H.C. Wainwright 4th Annual NASH Investor Conference, being held virtually on October 5, 2020.

  • Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study
    PR Newswire

    Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the last patient has been enrolled in its LiFT ("Liver Fat intervention with oral Testosterone") Phase 2 clinical study, a paired-biopsy study investigating LPCN 1144 in confirmed non-cirrhotic non-alcoholic steatohepatitis ("NASH") subjects. LPCN 1144 is an oral prodrug of endogenous testosterone. To date LPCN 1144 therapy has shown meaningful reductions of liver fat in our proof of concept liver fat imaging study in hypogonadal males and has demonstrated treatment potential in a pre-clinical NASH and hepatic fibrosis rabbit model. Moreover, no notable tolerability issues have been seen in 700+ hypogonadal subjects with up to 52-week exposure.